HeartSciences Statistics
Total Valuation
HeartSciences has a market cap or net worth of $9.85 million. The enterprise value is $8.78 million.
Important Dates
The last earnings date was Monday, December 15, 2025, after market close.
| Earnings Date | Dec 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HeartSciences has 3.18 million shares outstanding. The number of shares has increased by 116.09% in one year.
| Current Share Class | 3.18M |
| Shares Outstanding | 3.18M |
| Shares Change (YoY) | +116.09% |
| Shares Change (QoQ) | +113.30% |
| Owned by Insiders (%) | 3.74% |
| Owned by Institutions (%) | 7.04% |
| Float | 3.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,136.51 |
| Forward PS | n/a |
| PB Ratio | 2.27 |
| P/TBV Ratio | 4.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,012.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.42, with a Debt / Equity ratio of 0.21.
| Current Ratio | 2.42 |
| Quick Ratio | 1.25 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.00 |
Financial Efficiency
Return on equity (ROE) is -220.42% and return on invested capital (ROIC) is -85.98%.
| Return on Equity (ROE) | -220.42% |
| Return on Assets (ROA) | -74.78% |
| Return on Invested Capital (ROIC) | -85.98% |
| Return on Capital Employed (ROCE) | -186.00% |
| Revenue Per Employee | $578 |
| Profits Per Employee | -$602,426 |
| Employee Count | 15 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.01 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.37% in the last 52 weeks. The beta is 2.59, so HeartSciences's price volatility has been higher than the market average.
| Beta (5Y) | 2.59 |
| 52-Week Price Change | -19.37% |
| 50-Day Moving Average | 2.79 |
| 200-Day Moving Average | 3.35 |
| Relative Strength Index (RSI) | 59.91 |
| Average Volume (20 Days) | 74,196 |
Short Selling Information
The latest short interest is 29,118, so 0.92% of the outstanding shares have been sold short.
| Short Interest | 29,118 |
| Short Previous Month | 36,682 |
| Short % of Shares Out | 0.92% |
| Short % of Float | 0.95% |
| Short Ratio (days to cover) | 0.50 |
Income Statement
In the last 12 months, HeartSciences had revenue of $8,669 and -$9.04 million in losses. Loss per share was -$5.78.
| Revenue | 8,669 |
| Gross Profit | 5,021 |
| Operating Income | -8.24M |
| Pretax Income | -9.04M |
| Net Income | -9.04M |
| EBITDA | -8.21M |
| EBIT | -8.24M |
| Loss Per Share | -$5.78 |
Full Income StatementBalance Sheet
The company has $1.95 million in cash and $876,240 in debt, giving a net cash position of $1.07 million or $0.34 per share.
| Cash & Cash Equivalents | 1.95M |
| Total Debt | 876,240 |
| Net Cash | 1.07M |
| Net Cash Per Share | $0.34 |
| Equity (Book Value) | 4.18M |
| Book Value Per Share | 1.36 |
| Working Capital | 2.23M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.50 million and capital expenditures -$13,030, giving a free cash flow of -$7.51 million.
| Operating Cash Flow | -7.50M |
| Capital Expenditures | -13,030 |
| Free Cash Flow | -7.51M |
| FCF Per Share | -$2.36 |
Full Cash Flow StatementMargins
| Gross Margin | 57.92% |
| Operating Margin | -95,044.33% |
| Pretax Margin | -104,237.92% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HeartSciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -116.09% |
| Shareholder Yield | -116.09% |
| Earnings Yield | -91.72% |
| FCF Yield | -76.24% |
Analyst Forecast
The average price target for HeartSciences is $9.20, which is 196.77% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.20 |
| Price Target Difference | 196.77% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 17, 2024. It was a reverse split with a ratio of 1:100.
| Last Split Date | May 17, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
HeartSciences has an Altman Z-Score of -21.17 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -21.17 |
| Piotroski F-Score | 2 |
